Peptides Similar to Trevogrumab
Compare Trevogrumab with related peptides and alternatives
✓Reviewed byDr. Research Team(MD (composite credential representing medical review team), PhD in Pharmacology)
📅Updated February 12, 2026
Verified
📌TL;DR
- •4 similar peptides identified
- •Bimagrumab: undefined
- •Follistatin: undefined
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Trevogrumab (current) | - | - |
| Bimagrumab | ||
| Follistatin | ||
| GDF-8 (Myostatin) | ||
| Apitegromab |
Overview#
Trevogrumab operates within the myostatin/TGF-beta signaling pathway, which is targeted by several therapeutic approaches at different levels. Understanding the landscape of myostatin pathway modulators helps contextualize trevogrumab's selective approach and its position relative to broader-acting competitors.
Myostatin Pathway Modulators#
Point of Intervention Comparison#
| Therapy | Target | Mechanism | Specificity | Clinical Stage |
|---|---|---|---|---|
| Trevogrumab (REGN1033) | Myostatin (ligand) | Direct neutralization | Highly selective | Phase 2 |
| Bimagrumab (BYM338) | ActRIIA/ActRIIB (receptor) | Receptor blockade | Broad (multiple ligands) | Phase 2 |
| Apitegromab (SRK-015) | Latent myostatin | Prevents activation | Selective (latent form) | Phase 2/3 (SMA) |
| Garetosmab (REGN2477) | Activin A (ligand) | Direct neutralization | Selective | Phase 2 (with trevogrumab) |
| Follistatin | Multiple ligands | Natural neutralization | Moderate | Gene therapy/Research |
| Domagrozumab (PF-06252616) | Myostatin | Direct neutralization | Selective | Phase 2 (DMD, suspended) |
Trevogrumab vs Bimagrumab#
This is the most important competitive comparison, as both are being developed for obesity/body composition with GLP-1 agonist combinations.
| Feature | Trevogrumab | Bimagrumab |
|---|---|---|
| Developer | Regeneron/Sanofi | Novartis/Versanis/Lilly |
| Target | Myostatin (GDF-8) directly | ActRIIA/ActRIIB receptors |
| Ligand blockade | Myostatin only | Myostatin + activin A + GDF-11 + BMP-9/10 |
| Antibody class | IgG4-kappa | IgG1-lambda |
| Administration | Subcutaneous injection | Intravenous infusion |
| GLP-1 trial | COURAGE (with semaglutide) | BELIEVE (with semaglutide) |
| Trial size | 999 patients | 507 patients |
| Weight loss (combo) | -10.4% to -11.3% (26 wk) | -22.1% (48 wk) |
| Lean mass preservation | ~50% preserved | 67% more preserved |
| Monotherapy fat loss | Not primary endpoint | 20.5% fat loss (Phase 2 T2D) |
Key differences:
- Selectivity vs efficacy trade-off: Bimagrumab's broader blockade may provide greater body composition effects (simultaneous fat loss + lean mass gain), while trevogrumab's selectivity may offer a cleaner safety profile
- Administration convenience: Trevogrumab's SC route is a significant practical advantage over bimagrumab's IV infusion
- Combination approach: Regeneron addresses the selectivity gap by adding garetosmab (anti-activin A) as a triplet, approximating bimagrumab's broader blockade
Trevogrumab vs Apitegromab#
| Feature | Trevogrumab | Apitegromab (SRK-015) |
|---|---|---|
| Developer | Regeneron/Sanofi | Scholar Rock |
| Target | All myostatin forms | Latent myostatin only |
| Mechanism | Neutralizes active and latent myostatin | Blocks latent myostatin activation |
| Primary indication | Obesity/body composition | Spinal muscular atrophy (SMA) |
| Administration | SC injection | IV infusion |
| Clinical stage | Phase 2 (obesity) | Phase 2/3 (SMA) |
Apitegromab and trevogrumab target different disease contexts and employ complementary mechanisms within the myostatin pathway.
Trevogrumab vs Follistatin#
| Feature | Trevogrumab | Follistatin |
|---|---|---|
| Type | Human IgG4 antibody (~150 kDa) | Natural glycoprotein (~38 kDa) |
| Mechanism | Selective myostatin binding | Binds myostatin + activin A |
| Administration | SC injection | Gene therapy approaches under study |
| Clinical data | Phase 2 RCT (COURAGE) | Limited clinical data |
| Availability | Clinical trials only | Gene therapy/research |
| Half-life | ~21 days (expected) | Short (hours for protein form) |
Trevogrumab + Garetosmab vs Bimagrumab#
The combination of trevogrumab (anti-myostatin) + garetosmab (anti-activin A) creates a dual-ligand blockade strategy that mimics some aspects of bimagrumab's receptor-level blockade:
| Feature | Trevogrumab + Garetosmab | Bimagrumab |
|---|---|---|
| Approach | Two separate antibodies | Single antibody |
| Ligands blocked | Myostatin + Activin A | Myostatin + Activin A + GDF-11 + BMP-9/10 |
| Administration | SC + IV (two injections) | IV only (one infusion) |
| Lean mass preservation | 80.9% (COURAGE) | 67% more than semaglutide alone (BELIEVE) |
| Safety signal | Higher discontinuation (28.3%) | Well-tolerated |
GLP-1 Combination Landscape#
The competitive landscape for myostatin pathway + GLP-1 combinations:
| Combination | Trial | Status | Key Finding |
|---|---|---|---|
| Trevogrumab + semaglutide | COURAGE | Phase 2 (26-wk data) | ~50% lean mass preserved |
| Trevogrumab + garetosmab + semaglutide | COURAGE | Phase 2 (26-wk data) | ~81% lean mass preserved |
| Bimagrumab + semaglutide | BELIEVE | Phase 2b (48-wk data) | 67% more lean preserved |
| Bimagrumab + tirzepatide | Lilly trial | Terminated (T2D) | T2D arm stopped |
Key Differentiating Factors#
Advantages of Trevogrumab#
- Subcutaneous administration: SC injection vs bimagrumab's IV infusion
- Selective targeting: Myostatin-only blockade reduces off-target pathway risks
- Large Phase 2 trial: COURAGE enrolled 999 patients (vs 507 for BELIEVE)
- Modular combination approach: Can add garetosmab for enhanced effect
- Regeneron platform: VelocImmune technology for fully human antibodies with low immunogenicity
Limitations of Trevogrumab#
- Ceiling effect: Myostatin-only blockade preserves only ~50% of lean mass loss
- Triplet safety concerns: Adding garetosmab improves efficacy but worsens tolerability
- Earlier stage: 26-week data only (vs 48-week for bimagrumab BELIEVE)
- Conference data only: COURAGE results not yet peer-reviewed
- No monotherapy body composition data: Unlike bimagrumab's Phase 2 T2D fat loss data
Related Reading#
Frequently Asked Questions About Trevogrumab
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer